-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China's National Medical Security Administration recently announced the drugs and related information
that passed the preliminary formal review of the 2022 medical insurance drug list adjustment.
According to the list, a total of 344 drugs have passed the preliminary formal examination, including Azifedine tablets
, a Chinese domestic oral COVID-19 drug that has been included in the diagnosis and treatment plan for new crown pneumonia.
that passed the preliminary formal review of the 2022 medical insurance drug list adjustment.
According to the list, a total of 344 drugs have passed the preliminary formal examination, including Azifedine tablets
, a Chinese domestic oral COVID-19 drug that has been included in the diagnosis and treatment plan for new crown pneumonia.
According to the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (National Medical Insurance Drug Catalogue) to adjust the work arrangement, the National Medical Insurance Bureau recently conducted a preliminary formal review
of the declared drugs.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal review is not equivalent to being included in the national medical insurance drug list, and it is necessary to carry out expert review, negotiation and bidding in accordance with the
procedures.
of the declared drugs.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal review is not equivalent to being included in the national medical insurance drug list, and it is necessary to carry out expert review, negotiation and bidding in accordance with the
procedures.
According to the National Medical Insurance Bureau, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021, the number of drugs declared and passed the preliminary form examination has increased to a certain extent
.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
total of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021, the number of drugs declared and passed the preliminary form examination has increased to a certain extent
.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
This includes Azfding.
The drug is an oral small molecule new coronavirus pneumonia treatment drug independently developed by China and has been included in China's new crown pneumonia diagnosis and treatment plan
.
Reports indicate that the drug was officially put into production
in Henan Province in early August this year.
The drug is an oral small molecule new coronavirus pneumonia treatment drug independently developed by China and has been included in China's new crown pneumonia diagnosis and treatment plan
.
Reports indicate that the drug was officially put into production
in Henan Province in early August this year.
The National Medical Insurance Bureau said that in the context of the normalization of epidemic prevention and control, since the first implementation of the self-declaration system for medical insurance drug catalogue enterprises in 2020, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and has taken "drugs included in the "diagnosis and treatment plan for new coronavirus pneumonia" as one
of the declaration conditions.
A number of new crown treatment drugs have been included in the medical insurance drug list
.
of the declaration conditions.
A number of new crown treatment drugs have been included in the medical insurance drug list
.
This year, China's ninth edition of covid-19 protocol included a batch of drugs
that had just been marketed in China.
In the process of this declaration, some drugs have made self-declarations and passed the preliminary formal examination
.
For drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance catalogue
at a reasonable price.
that had just been marketed in China.
In the process of this declaration, some drugs have made self-declarations and passed the preliminary formal examination
.
For drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance catalogue
at a reasonable price.
Regarding how the work will be carried out after the announcement, the National Medical Insurance Bureau said that the next step will be to further verify the relevant information according to the feedback received during the publicity period, determine the scope of drugs that will eventually pass the formal examination, and announce it to the
public.
Subsequently, the National Medical Insurance Bureau will promote follow-up work
such as expert review, negotiation and bidding as planned.
(End)
public.
Subsequently, the National Medical Insurance Bureau will promote follow-up work
such as expert review, negotiation and bidding as planned.
(End)
China's National Medical Security Administration recently announced the drugs and related information
that passed the preliminary formal review of the 2022 medical insurance drug list adjustment.
According to the list, a total of 344 drugs have passed the preliminary formal examination, including Azifedine tablets
, a Chinese domestic oral COVID-19 drug that has been included in the diagnosis and treatment plan for new crown pneumonia.
that passed the preliminary formal review of the 2022 medical insurance drug list adjustment.
According to the list, a total of 344 drugs have passed the preliminary formal examination, including Azifedine tablets
, a Chinese domestic oral COVID-19 drug that has been included in the diagnosis and treatment plan for new crown pneumonia.
According to the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (National Medical Insurance Drug Catalogue) to adjust the work arrangement, the National Medical Insurance Bureau recently conducted a preliminary formal review
of the declared drugs.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal review is not equivalent to being included in the national medical insurance drug list, and it is necessary to carry out expert review, negotiation and bidding in accordance with the
procedures.
of the declared drugs.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal review is not equivalent to being included in the national medical insurance drug list, and it is necessary to carry out expert review, negotiation and bidding in accordance with the
procedures.
According to the National Medical Insurance Bureau, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021, the number of drugs declared and passed the preliminary form examination has increased to a certain extent
.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
Enterprise enterprisetotal of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with 2021, the number of drugs declared and passed the preliminary form examination has increased to a certain extent
.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
This includes Azfding.
The drug is an oral small molecule new coronavirus pneumonia treatment drug independently developed by China and has been included in China's new crown pneumonia diagnosis and treatment plan
.
Reports indicate that the drug was officially put into production
in Henan Province in early August this year.
The drug is an oral small molecule new coronavirus pneumonia treatment drug independently developed by China and has been included in China's new crown pneumonia diagnosis and treatment plan
.
Reports indicate that the drug was officially put into production
in Henan Province in early August this year.
The National Medical Insurance Bureau said that in the context of the normalization of epidemic prevention and control, since the first implementation of the self-declaration system for medical insurance drug catalogue enterprises in 2020, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and has taken "drugs included in the "diagnosis and treatment plan for new coronavirus pneumonia" as one
of the declaration conditions.
A number of new crown treatment drugs have been included in the medical insurance drug list
.
Pharmaceuticalsof the declaration conditions.
A number of new crown treatment drugs have been included in the medical insurance drug list
.
This year, China's ninth edition of covid-19 protocol included a batch of drugs
that had just been marketed in China.
In the process of this declaration, some drugs have made self-declarations and passed the preliminary formal examination
.
For drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance catalogue
at a reasonable price.
that had just been marketed in China.
In the process of this declaration, some drugs have made self-declarations and passed the preliminary formal examination
.
For drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance catalogue
at a reasonable price.
Regarding how the work will be carried out after the announcement, the National Medical Insurance Bureau said that the next step will be to further verify the relevant information according to the feedback received during the publicity period, determine the scope of drugs that will eventually pass the formal examination, and announce it to the
public.
Subsequently, the National Medical Insurance Bureau will promote follow-up work
such as expert review, negotiation and bidding as planned.
(End)
public.
Subsequently, the National Medical Insurance Bureau will promote follow-up work
such as expert review, negotiation and bidding as planned.
(End)
